+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients

Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients

Aaps Journal 16(5): 1018-1028

Quantitative prediction of the impact of chronic kidney disease (CKD) on drug disposition has become important for the optimal design of clinical studies in patients. In this study, clinical data of 151 compounds under CKD conditions were extensively surveyed, and alterations in pharmacokinetic parameters were evaluated. In CKD patients, the unbound hepatic intrinsic clearance decreased to a similar extent for drugs eliminated via hepatic metabolism by cytochrome P450, UDP-glucuronosyltransferase, and other mechanisms. Renal clearance showed a similar decrease to glomerular filtration rate, irrespective of the contribution of tubular secretion. The scaling factor (SF) obtained from the interquartile range of the relative change in each parameter was applied to the well-stirred model to predict clearance in patients. Hepatic and renal clearance could be successfully predicted for approximately half and two-thirds, respectively, of the applied compounds, showing the high utility of SFs. SFs were also introduced to a physiologically based pharmacokinetic (PBPK) model, and the plasma concentration profiles of 12 model compounds with different elimination pathways were predicted for CKD patients. The PBPK model combined with SFs provided good predictability for plasma concentration. The developed PBPK model with information on SFs would accelerate translational research in drug development by predicting pharmacokinetics in CKD patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051607584

Download citation: RISBibTeXText

PMID: 24912798

DOI: 10.1208/s12248-014-9626-3

Related references

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. European Journal of Pharmaceutical Sciences 112: 168-179, 2018

Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics 54(5): 567-568, 2015

Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach. Journal of Pharmaceutical Sciences 108(8): 2718-2727, 2019

Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals 45(4): 390-398, 2017

Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human. European Journal of Pharmaceutical Sciences 77: 265-272, 2015

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Frontiers in Immunology 5: 670, 2014

Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metabolism and Disposition: the Biological Fate of Chemicals 39(3): 383-393, 2011

Physiologically based pharmacokinetic model useful in prediction of the influence of species, dose, and exposure route on perchloroethylene pharmacokinetics. Journal of Toxicology and Environmental Health 44(3): 301-317, 1995

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Journal of Clinical Pharmacology 57(6): 796-804, 2017

Prediction of human pharmacokinetics from preclinical information of rhein, an antidiabetic nephropathy drug, using a physiologically based pharmacokinetic model. Basic and Clinical Pharmacology and Toxicology 114(2): 160-167, 2014

Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics. Journal of Pharmaceutical Sciences 102(11): 4193-4204, 2013

A physiologically-based pharmacokinetic PBPK approach to evaluate pharmacokinetics in patients with cancer. 2013

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. Journal of Clinical Pharmacology 52(1 Suppl): 91s, 2012

Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate. Biopharmaceutics and Drug Disposition 39(3): 125-134, 2018

Prediction of anticholinesterase activity and urinary metabolites of isofenphos: use of a percutaneous physiologically based pharmacokinetic-physiologically based pharmacodynamic model. ACS symposium series: 42) 284-380, 1994